Astrazeneca Plc (AZN)
NASDAQ:AZN
Holding AZN?
Track your performance easily

AstraZeneca (AZN) Income Statement

6,489 Followers

AstraZeneca Income Statement

Last quarter (Q4 2022), AstraZeneca's total revenue was $11.21B, a decrease of -6.69% from the same quarter last year. In Q4, AstraZeneca's net income was $901.00M. See AstraZeneca’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
$ 44.35B$ 45.81B$ 44.35B$ 37.42B$ 26.62B$ 24.38B
Cost of Revenue
$ 12.39B$ 8.27B$ 12.39B$ 12.44B$ 5.30B$ 4.92B
Gross Profit
$ 31.96B$ 37.54B$ 31.96B$ 24.98B$ 21.32B$ 19.46B
Operating Expense
$ 28.80B$ 28.82B$ 28.72B$ 25.11B$ 17.40B$ 18.77B
Operating Income
$ 3.15B$ 8.72B$ 3.24B$ -134.00M$ 3.92B$ 690.00M
Net Non Operating Interest Income Expense
$ -1.25B$ -1.29B$ -1.25B$ 1.23B$ 1.19B$ 1.24B
Other Income Expense
-$ -1.37B$ -923.00M---
Pretax Income
$ 2.50B$ 6.90B$ 2.90B$ -265.00M$ 3.92B$ 1.55B
Tax Provision
$ -792.00M$ 938.00M$ 792.00M$ -380.00M$ 772.00M$ 321.00M
Earnings From Equity Interest Net Of Tax
-$ -12.00M$ -5.00M---
Net Income Common Stockholders
$ 3.29B$ 5.96B$ 2.10B$ 112.00M$ 3.20B$ 1.33B
Basic EPS
-$ 3.84$ 2.12$ 0.08$ 2.44$ 1.03
Diluted EPS
-$ 3.81$ 2.11$ 0.08$ 2.44$ 1.03
Basic Average Shares
-$ 1.55B$ 1.55B$ 1.42B$ 1.31B$ 1.30B
Diluted Average Shares
-$ 1.56B$ 1.56B$ 1.43B$ 1.31B$ 1.30B
Dividend Per Share
-$ 2.90$ 2.90$ 2.80$ 2.81$ 2.83
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 41.20B$ 37.09B$ 41.11B$ -37.55B$ -22.70B$ -23.69B
Net Income From Continuing And Discontinued Operation
$ 3.29B$ 5.96B$ 2.10B$ 112.00M$ 3.20B$ 1.33B
Normalized Income
$ 2.92B$ 4.88B$ 2.13B$ -1.83B$ 1.93B$ -1.15B
Interest Expense
$ 1.33B-----
EBIT
$ 3.83B$ 8.49B$ 4.23B$ 1.01B$ 5.19B$ 2.95B
EBITDA
$ 9.08B$ 13.88B$ 9.71B$ 5.11B$ 8.08B$ 2.95B
Currency in USD

AstraZeneca Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis